Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 127

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 127
---
iring, such patents only cover certain components in the Company’s
products. Our additional subsequently granted patents provide supplementary protection, as well as the latest pending patent applications
which cover subsequent improvements in the Company’s products and processes. Furthermore, regulatory approval, when obtained, will
yield certain types of non-patent exclusivities that can maintain the Company’s advantage even after expiration of the earlier “basic
patent estate”.

<div align='center'>75</div>

We also have additional
subsequent patents that we believe could prevent competitors from entering the market when patents directed to the specific conjugate
molecules expire. The additional patents are directed to manufacturing processes, formulations and other important technologies and serve
to support and extend patent protection beyond the earliest patents. While it is a fact that the earliest patent families are due to
expire in the next few years, we believe that the newest patent applications will provide protection to the updated products and processes
for their manufacture. The latest patent applications, some of which have matured to patents, are designed to protect various improvements
to the earliest filed patents, including improvements to the process of production, and ready to use formulations that may be administered
from pre-filled syringes and do not require in situ addition of activators prior to use.

The latest family of patent
applications is derived from WO 2017/103924 (granted in China, India and Israel and filed in other territories), and the objectives the
Company aims to achieve with these applications are to seek to obtain patent protection to cover improved compositions which are being
used or which may be used by the Company in the future. The improved compositions that the Company aims to protect with these applications
relate to otherhydrogels that are formed using Gelrin’s conjugates of polyethylene glycol and denatured fibrinogen. In particular,
the conjugates are generated using an improved process that avoids the use of potentially harmful polar organic solvents and are ready
for use (GelrinC). The family of patent applications derived from WO 2017/103924 are granted in China, CN 108472413, India, IN 457479
and Israel, IL 259891 and includes pending patent application Nos. US 2022/0105240, EP 3389736, CA 3006695, and and JP 2023-180906, which
are detailed in the table below. . The pending patent applications are still in different stages of examination and may not